Literature DB >> 24735819

Insulin resistance and gray matter volume in neurodegenerative disease.

J K Morris1, E D Vidoni2, R D Perea3, R Rada4, D K Johnson5, K Lyons6, R Pahwa7, J M Burns8, R A Honea9.   

Abstract

The goal of this study was to compare insulin resistance in aging and aging-related neurodegenerative diseases, and to determine the relationship between insulin resistance and gray matter volume (GMV) in each cohort using an unbiased, voxel-based approach. Insulin resistance was estimated in apparently healthy elderly control (HC, n=21) and neurodegenerative disease (Alzheimer's disease (AD), n=20; Parkinson's disease (PD), n=22) groups using Homeostasis Model Assessment of Insulin Resistance 2 (HOMA2) and intravenous glucose tolerance test (IVGTT). HOMA2 and GMV were assessed within groups through General Linear Model multiple regression. We found that HOMA2 was increased in both AD and PD compared to the HC group (HC vs. AD, p=0.002, HC vs. PD, p=0.003), although only AD subjects exhibited increased fasting glucose (p=0.005). Furthermore, our voxel-based morphometry analysis revealed that HOMA2 was related to GMV in all cohorts in a region-specific manner (p<0.001, uncorrected). Significant relationships were observed in the medial prefrontal cortex (HC), medial temporal regions (AD), and parietal regions (PD). Finally, the directionality of the relationship between HOMA2 and GMV was disease-specific. Both HC and AD subjects exhibited negative relationships between HOMA2 and brain volume (increased HOMA2 associated with decreased brain volume), while a positive relationship was observed in PD. This cross-sectional study suggests that insulin resistance is increased in neurodegenerative disease, and that individuals with AD appear to have more severe metabolic dysfunction than individuals with PD or PD dementia.
Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Parkinson’s disease; dementia; glucose tolerance; insulin resistance; metabolism

Mesh:

Year:  2014        PMID: 24735819      PMCID: PMC4211112          DOI: 10.1016/j.neuroscience.2014.04.006

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  54 in total

1.  Evidence for adaptive cortical changes in swallowing in Parkinson's disease.

Authors:  Sonja Suntrup; Inga Teismann; Joke Bejer; Inga Suttrup; Martin Winkels; David Mehler; Christo Pantev; Rainer Dziewas; Tobias Warnecke
Journal:  Brain       Date:  2013-02-14       Impact factor: 13.501

2.  Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis.

Authors:  V A Skeberdis; J Lan; X Zheng; R S Zukin; M V Bennett
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

Authors:  B C Martin; J H Warram; A S Krolewski; R N Bergman; J S Soeldner; C R Kahn
Journal:  Lancet       Date:  1992-10-17       Impact factor: 79.321

4.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease.

Authors:  Claudia Ramaker; Johan Marinus; Anne Margarethe Stiggelbout; Bob Johannes Van Hilten
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

Review 5.  Neurodegenerative disorders associated with diabetes mellitus.

Authors:  Michael Ristow
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

Review 6.  The source of cerebral insulin.

Authors:  William A Banks
Journal:  Eur J Pharmacol       Date:  2004-04-19       Impact factor: 4.432

7.  Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging.

Authors:  Madhav Thambisetty; E Jeffrey Metter; An Yang; Hillary Dolan; Christopher Marano; Alan B Zonderman; Juan C Troncoso; Yun Zhou; Dean F Wong; Luigi Ferrucci; Josephine Egan; Susan M Resnick; Richard J O'Brien
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

Review 8.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery.

Authors:  Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

9.  Munc18c phosphorylation by the insulin receptor links cell signaling directly to SNARE exocytosis.

Authors:  Jenna L Jewell; Eunjin Oh; Latha Ramalingam; Michael A Kalwat; Vincent S Tagliabracci; Lixuan Tackett; Jeffrey S Elmendorf; Debbie C Thurmond
Journal:  J Cell Biol       Date:  2011-03-28       Impact factor: 10.539

10.  Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study.

Authors:  Weili Xu; Chengxuan Qiu; Margaret Gatz; Nancy L Pedersen; Boo Johansson; Laura Fratiglioni
Journal:  Diabetes       Date:  2008-10-24       Impact factor: 9.461

View more
  22 in total

Review 1.  Insulin resistance in ischemic stroke.

Authors:  Xiao-Ling Deng; Zhou Liu; Chuanling Wang; Yanfeng Li; Zhiyou Cai
Journal:  Metab Brain Dis       Date:  2017-06-21       Impact factor: 3.584

2.  Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin.

Authors:  Jill K Morris; Eric D Vidoni; Jonathan D Mahnken; Robert N Montgomery; David K Johnson; John P Thyfault; Jeffrey M Burns
Journal:  Neurobiol Aging       Date:  2015-12-01       Impact factor: 4.673

3.  Insulin resistance is associated with smaller brain volumes in a preliminary study of depressed and obese children.

Authors:  Owen R Phillips; Alexander K Onopa; Yevgeniya V Zaiko; Manpreet K Singh
Journal:  Pediatr Diabetes       Date:  2018-05-08       Impact factor: 4.866

Review 4.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

5.  Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.

Authors:  Therese S Salameh; Elizabeth M Rhea; Konrad Talbot; William A Banks
Journal:  Biochem Pharmacol       Date:  2020-08-02       Impact factor: 5.858

6.  Cardiovascular Risk Factors Associated with Smaller Brain Volumes in Regions Identified as Early Predictors of Cognitive Decline.

Authors:  Rajiv N Srinivasa; Heidi C Rossetti; Mohit K Gupta; Roger N Rosenberg; Myron F Weiner; Ronald M Peshock; Roderick W McColl; Linda S Hynan; Richard T Lucarelli; Kevin S King
Journal:  Radiology       Date:  2015-07-28       Impact factor: 11.105

7.  Late-Life Physical Activities Moderate the Relationship of Amyloid-β Pathology with Neurodegeneration in Individuals Without Dementia.

Authors:  Bo Kyung Sohn; Min Soo Byun; Dahyun Yi; So Yeon Jeon; Jun Ho Lee; Young Min Choe; Dong Woo Lee; Jun-Young Lee; Yu Kyeong Kim; Chul-Ho Sohn; Dong Young Lee
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

8.  Brain insulin resistance deteriorates cognition by altering the topological features of brain networks.

Authors:  Fan Su; Hao Shu; Qing Ye; Zan Wang; Chunming Xie; Baoyu Yuan; Zhijun Zhang; Feng Bai
Journal:  Neuroimage Clin       Date:  2016-12-12       Impact factor: 4.881

Review 9.  Perspectives in Lipocalin-2: Emerging Biomarker for Medical Diagnosis and Prognosis for Alzheimer's Disease.

Authors:  Juhyun Song; Oh Yoen Kim
Journal:  Clin Nutr Res       Date:  2018-01-17

Review 10.  Advanced glycation end-products: modifiable environmental factors profoundly mediate insulin resistance.

Authors:  Mona S Ottum; Anahita M Mistry
Journal:  J Clin Biochem Nutr       Date:  2015-07-01       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.